Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease
about
Alzheimer's disease--a panorama glimpseThe multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foesPurification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR SpectroscopyStructural Analysis and Aggregation Propensity of Pyroglutamate Aβ(3-40) in Aqueous TrifluoroethanolThe Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's DiseaseAlzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X.Pyroglutamate-Modified Amyloid-β(3-42) Shows α-Helical Intermediates before Amyloid Formation.The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradationA modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate Aβ peptides.Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease.Self-assembling peptide-based building blocks in medical applications.Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction.A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis.Modeling the Aggregation Propensity and Toxicity of Amyloid-β Variants.Isotope-edited FTIR reveals distinct aggregation and structural behaviors of unmodified and pyroglutamylated amyloid β peptides.Solid-Phase Synthesis and Characterization of N-Terminally Elongated Aβ-3-x -Peptides.N-truncated Aβ4-x peptides in sporadic Alzheimer's disease cases and transgenic Alzheimer mouse models.Plant-based chimeric HPV-virus-like particles bearing amyloid-β epitopes elicit antibodies able to recognize amyloid plaques in APP-tg mouse and Alzheimer's disease brains.Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-β42 in Alzheimer's disease.N-truncated Aβ2-X starting with position two in sporadic Alzheimer's disease cases and two Alzheimer mouse models.The role of astrocytes in amyloid production and Alzheimer's disease.The remarkable properties of amyloid-β derived from human Alzheimer's disease brain: swinging the streetlight.Purification of recombinant Aβ(1-42) and pGlu-Aβ(3-42) using preparative SDS-PAGE.Synergistic Effect on Neurodegeneration by N-Truncated Aβ4-42 and Pyroglutamate Aβ3-42 in a Mouse Model of Alzheimer's Disease.Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice.Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease.Nanogels of dual inhibitor-modified hyaluronic acid function as a potent inhibitor of amyloid β-protein aggregation and cytotoxicity.The McGill Transgenic Rat Model of Alzheimer's Disease Displays Cognitive and Motor Impairments, Changes in Anxiety and Social Behavior, and Altered Circadian Activity
P2860
Q27011749-49DD50B9-8FAC-4883-92A3-130BBAA52DCCQ27026919-1C23FF7F-8573-4499-B2FA-CE2D41065448Q28550062-ED3AFCB2-F56F-4AD7-9AD6-7676D77106F8Q28551142-9CCF8A7E-CD3A-4B17-B671-E48F20DB51DFQ33755982-9E4DD4E3-9139-4DD1-9A26-4D3061A46686Q36340365-C327B015-EB6D-4136-B9A6-9B38A113BEE0Q36356545-21C670C4-588C-479C-B577-93C45E3CAB68Q37085168-762FC16D-61FC-4A3C-8467-D5F66BB8CA6BQ37604055-D5ACA3C9-8AAF-4616-A156-CE7B24FC7913Q38297925-F9675D05-96FE-433A-A297-860880687D81Q38830346-E15A640E-5112-42F0-A14E-71F3FB3C25DEQ38831521-44B0A552-D3D7-455A-BF2C-D71D415E5535Q38913292-C685F3BE-DF3D-4EE0-989F-A1D495096EC0Q40506178-BF8FAF6A-9BF3-4920-8B72-3B77F163D31EQ40692757-EEDD7E9B-58B2-4C02-AF75-70FE8A2C4FCBQ41607465-0AE794C3-03E1-4168-A02A-26893CE94A71Q42278922-18A69211-FD4D-4453-A792-46F85174177EQ45325394-F6F6A19C-1F05-4382-9043-DB14523DAA0CQ46257047-A18C4381-FEA4-4C6A-B9B2-DAB6144CEF63Q46644527-766E396D-E854-445A-B643-5CAA0B60C774Q47296419-C541DE96-D345-4986-990F-7F0F1ACF6080Q48475706-81E46BEE-12E8-4630-B400-C5104898E0E4Q50641687-55F9CF35-A1BE-4835-8ABD-3E38D57F9615Q51760411-86BFE74E-5381-4EE0-9A42-24D9CD64A843Q52341984-3B935C65-C5E9-4F89-8284-2716552AE386Q52568535-1F7B1E5D-7411-4C2A-93AE-E9BCB5A66AC7Q54982684-56CFF8F6-B6DA-49A4-AE78-4CD8F1994FEEQ55006962-DCC9B927-9205-4FB5-81D0-B59F79899EE6Q58698284-30743D15-F41C-4062-8083-A88645C1D152
P2860
Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Focusing the amyloid cascade h ...... ts against Alzheimer's disease
@ast
Focusing the amyloid cascade h ...... ts against Alzheimer's disease
@en
type
label
Focusing the amyloid cascade h ...... ts against Alzheimer's disease
@ast
Focusing the amyloid cascade h ...... ts against Alzheimer's disease
@en
prefLabel
Focusing the amyloid cascade h ...... ts against Alzheimer's disease
@ast
Focusing the amyloid cascade h ...... ts against Alzheimer's disease
@en
P2860
P921
P1476
Focusing the amyloid cascade h ...... ts against Alzheimer's disease
@en
P2093
Thomas A Bayer
P2860
P2888
P304
P356
10.1007/S00401-014-1287-X
P577
2014-05-07T00:00:00Z
P5875
P6179
1044777348